Search clinical trials for: Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide

Total 864 results

National Research Center for Hematology, Russia

Recruiting

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Primary CNS Lymphoma

Russian Federation
Memorial Sloan Kettering Cancer Center
Columbia University; University of Vermont; University of Virginia; Northwestern... and other collaborators

Completed

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Lymphoma

United States
MD Anderson International Spain SA
Celgene Corporation

Completed

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia (LLC-LENAR-08)

Chronic Lymphocytic Leukemia

Spain
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.; Janssen Biotech, Inc.

Recruiting

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

United States
Hebei Yanda Hospital
Beijing Tiantan Hospital

Unknown

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Recurrent High-grade Glioma

China
European Organisation for Research and Treatment...
Medical Research Council

Completed

Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma

Brain and Central Nervous System Tumors

France, Switzerland, Netherlands, United Kingdom, Belgium, Germany, Italy, Sweden, Finland, Portugal, Austria, Hungary
Assistance Publique - Hôpitaux de Paris
French Innovative Leukemia Organisation

Unknown

Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine (CNSLymphoma)

Lymphoma

France
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology; Eastern Cooperative Oncology Group and other collaborators

Completed

Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma

Brain and Central Nervous System Tumors
Radiation Therapy Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaborators

Completed

Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma

Brain and Central Nervous System Tumors

United States
Institute of Cancer Research, United Kingdom

Completed

Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Canadian Cancer Trials Group; European Organisation...

Recruiting

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Brain and Central Nervous System Tumors

United States, Canada, France, Netherlands, Austria, Belgium
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

Brain and Central Nervous System Tumors

United States
Indiana University
Indiana University Melvin and Bren Simon Cancer Center

Completed

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Brain and Central Nervous System Tumors | Drug/Agent Toxicity by Tissue/Organ | Bone Marrow Suppression

United States
University Hospital Heidelberg
Ruhr University of Bochum; Universitätsmedizin Mannheim

Recruiting

A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (ImproveCodel)

Oligodendroglioma

Germany
Hee Young Ju

Not yet recruiting

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Lymphoblastic Leukemia in Children
Northwestern University
Pharmacyclics LLC.

Withdrawn

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Lymphoma | Brain and Central Nervous System Tumors | Neurotoxicity
Swiss Group for Clinical Cancer Research

Terminated

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Lymphoma

Switzerland, Norway, Sweden
Universität des Saarlandes
Spectrum Pharmaceuticals, Inc; German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine (OPTIMAL>60)

CD20+ Aggressive B-Cell Lymphoma

Germany
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

Lymphoma, Follicular

Italy
Institut Paoli-Calmettes

Completed

Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma (R2)

Non-Hodgkin Lymphoma

France
Roswell Park Cancer Institute
Celgene

Completed

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant

Lymphoma | Leukemia
University of Bologna

Terminated

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Italy
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

Lymphoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

Brain Tumors | Central Nervous System Tumors

United States, Canada, Australia, Switzerland, Netherlands, New Zealand
Weill Medical College of Cornell University
Celgene

Completed

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Guangdong Provincial People's Hospital
Guangzhou First People's Hospital; Foshan First People's Hospital; Huizhou Municipal... and other collaborators

Recruiting

Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years (R2DLBCL80)

Diffuse Large B Cell Lymphoma | Age Over 80 Years

China
Acrotech Biopharma Inc.

Completed

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United Kingdom, United States
Kim, Seok Jin
Celltrion; Samyang Biopharmaceuticals Corporation

Recruiting

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. (Lemon-C)

Primary CNS Lymphoma

Korea, Republic of
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

Austria
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
Henan Cancer Hospital

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Central Nervous System Lymphoma

China
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
Ruijin Hospital

Not yet recruiting

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Henan Cancer Hospital

Recruiting

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Henan Cancer Hospital

Active, not recruiting

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
The Lymphoma Academic Research Organisation

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

France
Chronic Lymphocytic Leukemia Research Consortium
Celgene Corporation

Unknown

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | CLL | Untreated | First-Line | Front-line | Initial Therapy

United States
Yan Zhang, MD
Peking University First Hospital; Chinese PLA General Hospital; Peking University...

Recruiting

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Diffuse Large B Cell Lymphoma

China
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

Primary Central Nervous System Lymphoma

Denmark, Finland, Italy, Israel, Switzerland
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

Brain and Central Nervous System Tumors

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Fred Hutchinson Cancer Center

Terminated

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | KSHV-associated Multicentric Castleman Disease

Uganda
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaborators

Terminated

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
University of Wisconsin, Madison
Genentech, Inc.; Celgene Corporation

Withdrawn

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)
University of Chicago
Celgene Corporation

Completed

Cetuximab and Lenalidomide in Head and Neck

Squamous Cell Carcinoma

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway

Search clinical trials for: Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations